Drug Trial Radar · NCT02791763
Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
Last checked: Nov 19, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
355
Actual
Start
Jun 6, 2016
Primary completion
Oct 26, 2018
Study completion Oct 26, 2018
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 7, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, open-label, active-controlled, parallel-group, multi-center study to compare the efficacy and safety of GSK1278863 administered for 52 weeks versus epoetin beta pegol in approximately 286 Japanese ND and 50 PD subjects with renal anemia. The study will consist of three cohorts. Cohort 1 and Cohort 3 will consist of ND subjects (Erythropoiesis-Stimulating Agent \[ESA\] users and ESA non-users) randomized to receive GSK1278863 or epoetin beta pegol in a ratio of 1:1. PD subjects will be enrolled into Cohort 2 and will receive GSK1278863. This study consists of a 4-week screening phase, a 52-week treatment phase (including primary efficacy evaluation period \[Weeks 40 to 52\]), and a 4-week follow-up phase following the treatment phase. The primary objective of this study is to demonstrate non-inferiority of GSK1278863 to epoetin beta pegol based on mean hemoglobin (Hgb) during the primary efficacy evaluation period in ND subjects. ESA non-users from Cohort 1 will be excluded from the primary efficacy analysis. Study results will be used as pivotal study data for an NDA submitted for GSK1278863 for the treatment of renal anemia in Japan.
Conditions
- Anaemia
Interventions
1 to 4 mg tablets of GSK1278863Drug
7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
6 mg GSK1278863 tabletDrug
9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
Epoetin beta pegolDrug
An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND ParticipantsTime frame: Weeks 40 to 52
Locations
56 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Aichi, Japan
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Ehime, Japan
GSK Investigational Site
Fukui, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukuoka, Japan
GSK Investigational Site
Fukushima, Japan
GSK Investigational Site
Gifu, Japan
GSK Investigational Site
Gifu, Japan
GSK Investigational Site
Hiroshima, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Ibaraki, Japan
GSK Investigational Site
Ishikawa, Japan
GSK Investigational Site
Ishikawa, Japan
GSK Investigational Site
Kagoshima, Japan
GSK Investigational Site
Kagoshima, Japan
GSK Investigational Site
Kagoshima, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Kumamoto, Japan
GSK Investigational Site
Kumamoto, Japan
GSK Investigational Site
Kyoto, Japan
GSK Investigational Site
Kyoto, Japan
GSK Investigational Site
Kyoto, Japan
GSK Investigational Site
Nagano, Japan
GSK Investigational Site
Nagano, Japan
GSK Investigational Site
Numakunai, Japan
GSK Investigational Site
Ōita, Japan
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.